Table 3.
Efficacy variables | Treatment group | N | Number (%) of participants | p-value | Number-needed-to-treat (95% CI) |
50% reduction in pain | Topical diclofenac | 105 | 46 (43.8) | 0.004 | 5 (3–17) |
Vehicle control | 107 | 27 (25.2) | |||
OMERACT-OARSI responder* | Topical diclofenac | 105 | 69 (65.7) | 0.017 | 6 (3–33) |
Vehicle control | 107 | 53 (49.5) | |||
Good or very good PGA response | Topical diclofenac | 105 | 46 (43.8) | <0.0001 | 4 (3–7) |
Vehicle control | 107 | 18 (16.8) |
*A responder is defined as a participant with ≥ 50% improvement in pain or function that was ≥ 20% of the scale, or ≥ 20% improvement in at least two of pain, function or patient global assessment that was ≥ 10% of the scale.